Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amrubicin vs Topotecan in Second-Line Sensitive SCLC
NCT00319969Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2006
- Primary completion
- Jul 2008
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of amrubicin in small cell lung cancer (SCLC), sponsored by Celgene Corporation. Started Apr 2006; status: completed.
02
Drugs
amrubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00319969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00319969.